ALLR Allarity Therapeutics, Inc.
Price Chart
Executive Summary
Allarity Therapeutics reported full-year 2025 financial results, showing improved net loss of $11.2 million (vs $25.1 million in 2024) due to cost discipline, while securing a $20 million debt financing and receiving FDA Fast Track designation for stenoparib in advanced ovarian cancer. The company also launched a VA-funded combination trial in small cell lung cancer.
Actionable Insight
The FDA Fast Track designation and successful $20 million financing materially de-risk stenoparib's development path; monitor upcoming clinical trial enrollment and data readouts as key catalysts. The new license revenue stream validates the DRP platform's commercial potential.
Key Facts
- Net loss improved to $11.2 million in 2025 from $25.1 million in 2024, excluding a $9.7 million non-cash impairment in 2024
- Received FDA Fast Track designation for stenoparib in advanced ovarian cancer
- Closed $20 million non-convertible debt financing with Streeterville Capital in March 2026
- Launched Phase 2 combination trial of stenoparib with temozolomide in recurrent small cell lung cancer, fully funded by the U.S. Veterans Administration
- Generated $320,000 in license revenue in 2025, compared to no revenue in 2024
Financial Impact
Net loss improved by $13.9 million year-over-year (excluding 2024 impairment), with $320,000 in new license revenue and $20 million in new debt financing
Risk Factors
- High cash burn rate despite improvements; $14.7 million cash at year-end 2025 may not cover runway to mid-2028 as projected
- Clinical trial delays or negative data could jeopardize Fast Track status and commercial prospects
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-038061 |
| Document: ea0279571-8k_allarity.htm | 0001213900-26-038061 |
| Document: 0001213900-26-038061-index-headers.html | 0001213900-26-038061 |
| Document: 0001213900-26-038061-index.html | 0001213900-26-038061 |
| Document: 0001213900-26-038061.txt | 0001213900-26-038061 |
| 8-K Data (Synthetic) | 0001213900-26-038061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 11, 2026
12d ago
|
3
| $1.68 $1.43 | ▼ −14.88% | ▼ −14.80% | $1.77 (+5.36%) |
|
May 8, 2026
15d ago
|
Press Release
| $1.55 $1.51 | ▼ −2.58% | ▼ −4.04% | $1.77 (+14.19%) |
|
May 6, 2026
17d ago
|
8-K
| $1.48 $1.52 | ▲ +2.70% | ▲ +1.57% | $1.77 (+19.59%) |
|
Apr 27, 2026
26d ago
|
Press Release
| $1.37 $1.25 | ▼ −8.76% | ▼ −9.16% | $1.77 (+29.20%) |
|
Apr 27, 2026
26d ago
|
EFFECT
| $1.37 $1.25 | ▼ −8.76% | ▼ −9.16% | $1.77 (+29.20%) |
|
Apr 24, 2026
29d ago
|
S-3/A
| $1.34 $1.35 | ▲ +0.75% | ▼ −0.16% | $1.77 (+32.09%) |
|
Apr 22, 2026
4w ago
|
8-K
| $1.40 $1.39 | ▼ −0.81% | ▼ −0.87% | $1.77 (+26.43%) |
|
Apr 1, 2026
7w ago
|
8-K
| $1.13 $1.15 | ▲ +1.77% | ▼ −2.00% | $1.77 (+56.64%) |
|
Mar 31, 2026
7w ago
|
Press Release
| $1.09 $1.16 | ▲ +6.42% | ▲ +2.48% | $1.77 (+62.39%) |
|
Mar 6, 2026
11w ago
|
Press Release
| $1.24 $1.26 | ▲ +1.61% | ▲ +3.14% | $1.77 (+42.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access